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Abstract
Background: The trafficking of mitochondria within neurons is a highly regulated process. In an earlier study, we found that
serotonin (5-HT), acting through the 5-HT1A receptor subtype, promotes axonal transport of mitochondria in cultured
hippocampal neurons by increasing Akt activity, and consequently decreasing glycogen synthase kinase (GSK3b) activity.
This finding suggests a critical role for neuromodulators in the regulation of mitochondrial trafficking in neurons. In the
present study, we investigate the effects of a second important neuromodulator, dopamine, on mitochondrial transport in
hippocampal neurons.
Methodology/Principal Findings: Here, we show that dopamine, like 5-HT, regulates mitochondrial motility in cultured
hippocampal neurons through the Akt-GSK3b signaling cascade. But, in contrast to the stimulatory effect of 5-HT,
administration of exogenous dopamine or bromocriptine, a dopamine 2 receptor (D2R) agonist, caused an inhibition of
mitochondrial movement. Moreover, pretreatment with bromocriptine blocked the stimulatory effect of 5-HT on
mitochondrial movement. Conversely, in cells pretreated with 5-HT, no further increases in movement were observed after
administration of haloperidol, a D2R antagonist. In contrast to the effect of the D2R agonist, addition of SKF38393, a
dopamine 1 receptor (D1R) agonist, promoted mitochondrial transport, indicating that the inhibitory effect of dopamine
was actually the net summation of opposing influences of the two receptor subtypes. The most pronounced effect of
dopamine signals was on mitochondria that were already moving directionally. Western blot analysis revealed that
treatment with either a D2R agonist or a D1R antagonist decreased Akt activity, and conversely, treatment with either a D2R
antagonist or a D1R agonist increased Akt activity.
Conclusions/Significance: Our observations strongly suggest a role for both dopamine and 5-HT in regulating
mitochondrial movement, and indicate that the integrated effects of these two neuromodulators may be important in
determining the distribution of energy sources in neurons.
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Introduction
It has been shown that axonal transport of mitochondria
ensures proper neuronal function [1]. Aberrant mitochondrial
trafficking has been linked to a number of neurodegenerative
disorders, including Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease, and Lou Gehrig’s disease [2–4]. Although
several signals have been found to modulate mitochondrial
trafficking in neurons [5–8], the precise roles of these signals have
not been fully characterized.
Previously, we identified serotonin (5-HT) as an extracellular
signal that can promote axonal mitochondrial movement in
cultured hippocampal neurons, suggesting a possible relationship
between neuronal activity and mitochondrial movement [9]. In
the same study, we demonstrated the importance of the Akt-
GSK3b signaling cascade in the control of mitochondrial
trafficking in response to 5-HT signaling. Direct inhibition of
Akt suppressed mitochondrial trafficking, whereas inhibition of
GSK3b, which is directly phosphorylated, and thus inhibited, by
Akt, enhanced trafficking [9]. These results indicate a general role
for this pathway in the control of mitochondrial movement, and
suggest that other signals converging on the Akt-GSK3b pathway
may also affect the trafficking of mitochondria. Interestingly,
dopamine has recently been shown to act through the Akt-GSK3b
pathway in striatal neurons [10–12].
Dopamine is an important neurotransmitter that is involved in
many aspects of neural function, including motor activity,
emotion, reward, sleep, and learning [13–15]. Although it has
been suggested that the effects of dopamine in disorders such as
Parkinson’s disease and schizophrenia are linked to impaired
mitochondrial function [16,17], an influence of dopamine on
mitochondrial movement has not been reported.
With the foregoing considerations in mind, we decided to
investigate the effect of dopamine on mitochondrial trafficking.
Based on the analysis of data from time-lapse imaging of cultured
hippocampal neurons, we report here that dopamine has a net
inhibitory effect on mitochondrial movement. Specifically, where-
as activation of the D2 receptor inhibited the movement of
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movement of mitochondria. Consistent with their effects on
mitochondrial motility, dopamine agonists and antagonists also
showed opposing effects on the Akt-GSK3b signaling cascade, the
same pathway that is activated by 5-HT in modulating
mitochondrial motility in hippocampal neurons [9]. When we
stimulated mitochondrial movement with 5-HT, then added a
D2R agonist, movement was strongly reduced. However,
treatment with a D1R agonist did not cause an increase in
trafficking above that induced by 5-HT. These observations point
to a possible physiological role for both dopamine and 5-HT in
regulating mitochondrial movement in hippocampal neurons.
Previously, it has been suggested that dopamine and 5-HT signals
can interact coordinately to regulate neuronal activity in the
striatum [11,18]; however, the coordinate regulation of mitochon-
drial motility by these two neurotransmitters in hippocampal
neurons is a novel finding.
Results
Dopamine inhibits mitochondrial motility in
hippocampal neurons
As described in our earlier study of 5-HT and mitochondrial
transport [9], we employed fully differentiated and spontaneously
active hippocampal neurons as a model culture system. Consistent
with the finding that the dopamine receptor subtypes, D1 and D2,
colocalize in neostriatal neurons [19], we found a similar pattern
of expression in nearly all of the cultured hippocampal neurons
that we imaged (Fig. 1A–D and Fig. 2A), including evidence of
punctate immunoreactivity associated with axons (Fig. 2B–D).
Cultures were infected with the Flx1.8/MitoEYFP lentivirus [9]
and used in live imaging experiments. Images were collected for
2 hours prior to the addition of dopamine (30 nM), and then for
2 hours after exposure to dopamine (representative time-lapse
movies are available in Supporting Information). Following the
same criteria used previously, patterns of mitochondrial motility
during long-term observation were categorized into three distinct
groups: a stationary population, an oscillatory population, and a
directionally moving population [9]. A mitochondrion was
classified as stationary if it moved less than 0.2 mm (equivalent
to 2 pixels; 1 pixel=0.10235 um under 636magnification) over
the period of observation. A mitochondrion was considered to be
oscillatory if it moved bidirectionally at least 0.2 mm—but not
more than 2.5 mm—around a fixed point during the period of
observation. A mitochondrion was considered to move direction-
ally, either anterogradely or retrogradely, if it was observed to
travel a distance greater than 2.5 mm within the axon. The same
classification scheme was also applied in the analysis of dendritic
mitochondria (data not shown).
Following a method described previously [9], the mean speed of
each individual mitochondrion in the axonal segment under
observation was calculated from the cumulative distance traveled
over the entire period of observation. The initial relative position
of each mitochondrion along the axonal segment is shown on the
y-axis in Fig. 3A and B. The average numbers of stationary,
oscillatory, and directionally moving mitochondria were obtained
from time-lapse images taken in the first and last 15 minutes of
each experiment (pie chart insets, Fig. 3A, B). Prior to treatment
with dopamine (30 nM), most axonal mitochondria (,77%) were
either stationary or moved in an oscillatory manner (Fig. 3A, pie
Figure 1. The dopamine receptor subtypes, D1R and D2R, are both expressed in cultured hippocampal neurons (A–D). D1 receptors
are shown in red (A); D2 receptors are shown in green (B); MAP2 expression (soma and dendrites) is shown in blue (C); the merged image (D) indicates
colocalization (yellow).
doi:10.1371/journal.pone.0002804.g001
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dopamine, the directionally moving mitochondria slowed down
dramatically, and at the end of two hours, all directional
movement was inhibited (compare Fig. 3A, B, and corresponding
pie chart insets; Movies S1 and S2). The oscillatory population was
also significantly diminished. To determine the time of onset of the
effect of dopamine on mitochondrial motility, the mean speeds of
all directionally moving mitochondria were binned every 15 min-
utes two hours before and two hours after treatment. As shown in
Fig. 3C, there was already a dramatic decrease in the rate of
mitochondrial movement 15 minutes after the administration of
dopamine. Within 45 minutes following treatment, virtually all
mitochondria had essentially stopped moving. Each data set was
obtained from five paired time-lapse imaging experiments (five
separately prepared cultures, each imaged for 2 h before and 2 h
after dopamine treatment; a total of 236 mitochondria tracked).
Given the observed inhibitory effect of dopamine on mitochon-
drial motility, we were concerned that the mitochondria in our
cultured neurons had been directly impaired by exposure to
exogenous monoamine. In other studies of mitochondrial motility,
inhibitory effects on mitochondrial movement have generally been
consistent with mitochondrial impairment, indicated by a loss of
membrane potential and drastic changes in mitochondrial mor-
phology [7,8,20,21]. However, we didnot observe any obvioussigns
of toxicity in neurons treated with the amount of dopamine that we
administered; nor did we see any change in mitochondrial
membrane potential as visualized with the vital dye JC-1 (Movie
S3). As expected, when carbonylcyanide p-trifluoromethoxyphe-
nylhydrazone (FCCP),an uncoupler, wasadded to a parallel culture
as a positive control, JC-1 fluorescence was extinguished over time,
indicating a loss of membrane potential (Movie S4).
A D2R agonist inhibits mitochondrial transport, whereas
a D2R antagonist promotes mitochondrial transport
Administration of the dopamine 2 receptor (D2R) agonist,
bromocriptine (5 mM), in the absence of added dopamine
markedly inhibited both directional and oscillatory movement of
mitochondria (compare Fig. 4A and B, pie chart insets a and b;
Movies S5 and S6). Based on an analysis of time-lapse image
sequences from five separate paired experiments (five separately
prepared cultures, each imaged for 2 h before and 2 h after
treatment with bromocriptine; a total of 227 mitochondria
tracked), it appeared that activation of the D2 receptor induced
mitochondria that had previously been moving directionally to
stop moving entirely. As shown in Fig. 4C, bromocriptine showed
a dramatic dampening effect on mitochondrial motility within
15 minutes following treatment (Fig. 4C).
To further investigate the role of the D2 receptor in regulating
mitochondrial movement, we examined the effects of a D2R
antagonist on cultured hippocampal neurons. In contrast to the
effect of bromocriptine, administration of the D2R antagonist,
haloperidol (10 mM), in the absence of added dopamine
significantly stimulated mitochondrial movement; the majority of
this movement was anterograde (e.g., toward the axonal terminal)
(Fig. 4D, E; Movies S7 and S8). Although an analysis of images
from six paired time-lapse imaging experiments (six separately
prepared cultures, each imaged for 2 h before and 2 h after
haloperidol treatment; a total of 288 mitochondria tracked) did not
show much increase in the size of the directionally moving
population (Fig. 4D, E; pie chart insets a and b), starting at
30 minutes, there was a marked increase in the average speed of
all directionally moving mitochondria (Fig. 4F) that reached 1.8-
fold of the control population after 2 hours (n=6, paired t-test;
Figure 2. Both dopamine receptor subtypes are expressed in the same hippocampal neurons (A–D). A. A typical pyramidal neuron that
was used in mitochondrial motility studies shows expression of both D1 and D2 receptors (A, top panel). D1 receptors (D1R) are shown in red
(bottom, left panel); D2 receptors (D2R) are shown in green (bottom, middle panel); MAP2 expression (soma and dendrites) is shown in blue (bottom,
right panel). The merged image (A) indicates colocalization (yellow). B–D. Detail of expression of D1R (B) and D2R (C) in axons (enlargement of
rectangular region indicated by red dashed border in A); merged image of D1R and D2R labeling is shown in D (labeling of axon has been removed
for clarity). Axons in B and C are immunolabeled with phospho-neurofilament (pNF) antibody (purple).
doi:10.1371/journal.pone.0002804.g002
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any endogenous dopamine in the cultures. In earlier studies,
dopamine uptake by cultured rat astrocytes was demonstrated
[22,23], suggesting that astrocytes might be a possible source of
endogenous dopamine in our culture system, in which we use glia-
conditioned media.
A D1R agonist promotes mitochondrial transport,
whereas a D1R antagonist inhibits mitochondrial
movement
D1 receptors are the second major class of dopamine receptors
found in hippocampal neurons (Figs. 1, 2). Since signals from D2R
and D1R may have opposing effects [19,24], we decided to
investigate the possible effect of a D1R-specifc agonist on
mitochondrial movement. Administration of the D1R agonist,
SKF38393 (33 mM), markedly stimulated mitochondrial movement,
primarily anterogradely, toward the axon terminal (Fig. 5A, B;
Movies S9 and S10). Analysis of six paired time-lapse imaging
experiments (six separately prepared cultures, each imaged for 2 h
before and 2 h after treatment with SKF38393; a total of 252
mitochondria tracked) showed a slight increase in the size of the
directionally moving population (Fig. 5B, pie chart insets a and b).
There was also a slight increase in the mean speed of directionally
moving mitochondria approximately one hour following the
treatment. After 2 hours, the average speed of all directionally
moving mitochondria had increased by 65% compared to the
2 hours prior to drug treatment (Fig. 5C; n=6, paired t-test; p,0.02).
Figure 3. Dopamine inhibits axonal transport of mitochondria in hippocampal neurons (A–C). A, B. Mean speeds (mm/min) of individual
mitochondria before (A) and after (B) treatment with dopamine (30 nM). Pie chart insets show the percentage of stationary (red), oscillatory (blue),
and directionally moving (green) mitochondria in all pooled experiments in the initial (a) and final (b) 15 minutes of imaging. C. Changes in mean
speeds of all directionally moving mitochondria over time following treatment with dopamine. ‘‘(2)’’ indicates retrograde movement; ‘‘(+)’’ indicates
anterograde movement. The red dotted lines projecting from the highlighted region of the schematic axon to the Y-axis of each graph in A and B
indicate the approximate location (,100–150 mm from the soma) and extent (,50–80 mm) of the axon segment that was imaged.
doi:10.1371/journal.pone.0002804.g003
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experiments (five separately prepared cultures, each imaged for
2 h before and 2 h after treatment with SCH23390; a total of 287
mitochondria tracked) showed that administration of the D1R
antagonist, SCH23390 (55 mM), inhibited virtually all directional
movement of mitochondria within one hour, and dramatically
decreased oscillatory movement (Fig. 5D, E; pie chart insets a and
b; 5F; Movies S11 and S12).
Mitochondrial transport is reversibly modulated by
sequential activation of D2R and D1R receptors
As shown in Figures 1 and 2, we found that both D2R and D1R
are expressed in the same hippocampal neurons. Since dopamine,
which stimulates both D1R and D2R, blocks mitochondrial
movement, a D2R-dependent ‘stop’ signal must predominate over
a D1R-mediated ‘go’ signal. We wished to determine whether the
effect of D2R activation was reversible, and whether inhibited
mitochondria could be re-induced to move by subsequent
activation of D1R within the same neuron. When we sequentially
added bromocriptine, and then SKF38393, after washout of the
D2R agonist, we observed that mitochondrial movement was
inhibited and then subsequently enhanced following exposure to
the D1R agonist. Addition of SKF38393 failed to restore
mitochondrial movement without washing out the bromocriptine,
the D2R agonist (data not shown). In this experiment, we
employed a red fluorescent protein, which allowed us to acquire
images continuously every 10 seconds over a period of 4 hours
without any observable phototoxicity (Movies S13-S16). To
illustrate this result, we present the data as kymographs (Fig. 6).
This experiment demonstrates unambiguously that mitochondrial
movement can be reversibly modulated by differential activation
of the two dopamine receptor subtypes.
The Akt-GSK3b signaling pathway is involved in
dopamine-mediated regulation of mitochondrial
movement
Previously, using inhibitors of Akt or GSK3b and phospho-
specific antibodies in a Western blot analysis, we showed that the
Akt-GSK3b signaling pathway is explicitly involved in the
modulation of mitochondrial movement in response to stimulation
by 5-HT [9]. We employed the same method here to determine if
the Akt-GSK3b signaling cascade might also modulate the effects
of dopamine on mitochondrial movement. Western blot analysis
showed that the Akt-GSK3b signaling pathway is strongly
implicated in dopamine signaling in hippocampal neurons treated
with different dopamine agonists and antagonists. When neurons
were treated with dopamine alone (30 nM), levels of activated Akt
(pAkt) decreased by 50% (Fig. 7A, B). In agreement with our
imaging data (Fig. 3), the effect of dopamine administration on the
phosphorylation of Akt was evident after 15 minutes (Fig. S1).
Treatment with the D2R agonist, bromocriptine (5 mM; Fig. 7C,
lane 2), or the D1R antagonist, SCH23390 (55 mM; Fig. 7C, lane
5) also decreased levels of pAkt by more than 75% and 50%,
respectively (Fig. 7D, top panel, columns 2 and 5). As well, after
treatment with bromocriptine or SCH23390, levels of inactivated
GSK3b (pGSK3b) were decreased by 25% (Fig. 7D, bottom
panel, columns 2 and 5). Conversely, treatment with the D2R
antagonist, haloperidol (10 mM; Fig. 6C, lane 3), or the D1R
agonist, SKF38393 (33 mM; Fig. 7C, lane 4), increased levels of
both pAkt and pGSK3b, by 75% and 30%, respectively (Fig. 7D,
bottom panel, columns 3 and 4).
Given the importance of the cAMP pathway in dopamine
signaling [24,25], we decided to elevate cAMP levels directly in
hippocampal neurons by treating cultures with 3-isobutyl-1-
methylxanthine (IBMX, 100 mM). In the striatum, D1R signaling
is coupled to an increase in adenylyl cyclase activity [24,25]; we
therefore anticipated that IBMX treatment might cause an
increase in mitochondrial movement. However, as shown in
Figure 8A, the mean speed of mitochondrial movement (averaged
over the entire imaging session) was dramatically reduced (Movies
S17 and S18). Moreover, within 15 minutes, treatment with
IBMX led to a decrease in Akt activity that was sustained over at
least 60 minutes (Fig. 8B). These results are consistent with the
idea that dopamine receptors in hippocampal neurons are coupled
to a different downstream signaling pathway than the same
receptors in striatal neurons. In support of this interpretation,
when we treated striatal neurons with IBMX, we observed an
increase in Akt activation, as previously reported [26] (Fig. 8C).
5-HT and dopamine exert opposing effects in the
regulation of mitochondrial movement
We have shown previously that exogenous 5-HT promotes
mitochondrial trafficking in cultured hippocampal neurons [9]. In
the present study, we found that dopamine exerts a net inhibitory
effect on mitochondrial movement in the same model system
(Fig. 3). It is therefore possible that the two neurotransmitters have
opposing effects on mitochondrial movement, given that the Akt-
GSK3b signaling pathway is affected by both signals. To explore
this possibility, we performed experiments in which 5-HT and
dopamine receptor agonists and antagonists were added sequen-
tially in different combinations to the same culture and their
cumulative effects on mitochondrial movements were observed
over time using time-lapse fluorescence microscopy (Figs. 9A, C)
and by Western blot analysis to detect activated Akt levels under
the same conditions (Figs. 9B, D). The results of these experiments
showed that inhibition of mitochondrial movement by dopamine,
a D2R agonist, or a D1R antagonist was not reversed by
subsequent addition of 5-HT (Fig. 9A). Moreover, the increased
speed of moving mitochondria induced by treatment with either a
D2R antagonist or a D1R agonist was not further enhanced by
subsequent treatment with 5-HT (Fig. 9A). Western blot analysis
of cultures treated with the same drug regimen showed that Akt
phosphorylation remained below control levels in the presence of
dopamine, bromocriptine, or SCH23390 even after addition of 5-
HT. In an earlier study, we showed that the addition of 5-HT
increases Akt phosphorylation [9]. In the present study, Akt
phosphorylation remained elevated in the presence of either
SKF38393 or haloperidol and 5-HT (Fig. 9B). In contrast to these
observations, when hippocampal neurons were pretreated with 5-
HT, the subsequent addition of a dopamine D2R agonist led to a
Figure 4. Bromocriptine, a D2R agonist, inhibits axonal transport of mitochondria in hippocampal neurons, whereas Haloperidol, a
D2R antagonist, promotes mitochondrial transport (A–F). A–B and D–E. Mean speeds (mm/min) of individual mitochondria before and after
treatment with Bromocriptine (5 mM; A,B) or Haloperidol (10 mM; D,E). Pie chart insets show the percentage of stationary (red), oscillatory (blue), and
directionally moving (green) mitochondria in all pooled experiments in the initial (a) and final (b) 15 minutes of imaging. C,F. Changes in mean
speeds of all directionally moving mitochondria over time following treatment with D2R agonists and antagonists. ‘‘(2)’’ indicates retrograde
movement; ‘‘(+)’’ indicates anterograde movement. The red dotted lines projecting from the highlighted region of the schematic axon to the Y-axis of
each graph indicate the approximate location (,100–150 mm from the soma) and extent (,50–80 mm) of the axon segment that was imaged.
doi:10.1371/journal.pone.0002804.g004
Dopamine and Mitochondria
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However, neither the D2R antagonist nor the D1R agonist
stimulated mitochondrial movement beyond levels observed after
administration of 5-HT alone (Fig. 9C). As shown in Figure 9D,
the addition of dopamine or bromocriptine caused a decrease in
Akt phosphorylation, whereas Akt phosphorylation again re-
mained elevated in the presence of either SKF38393 or
haloperidol and serotonin. To confirm that the effect of dopamine
or bromocriptine was reversible, these drugs were washed out
before adding 5-HT or the D1R agonist, SKF38393 (Fig. S2).
Discussion
Dopamine has a net inhibitory effect on mitochondrial
movement in hippocampal neurons
Dopamine is an important neurotransmitter in the regulation of
many aspects of neural function. Changes in levels of dopamine, as
well as in the dynamic activity of mitochondria, have been
implicated in the onset of symptoms in both Parkinson’s disease
and schizophrenia [16,17]. Hitherto, no direct observations have
been reported of the effect of dopamine on mitochondrial
trafficking. In the present study, we found that dopamine
dramatically inhibited mitochondrial movement in cultured
hippocampal neurons. Although we observed a similar net
inhibitory effect of dopamine on mitochondrial movement in
dendrites, the high density of mitochondria at the proximal ends of
these processes, as well as possible fission and fusion events at their
distal ends, prevented us from performing precise quantification.
A number of studies have reported that dopamine is toxic to
neurons in vitro [27,28]. However, neurotoxicity likely follows from
exposure to relatively high amounts of dopamine [28], well in
excess of physiologically relevant dosages. In our studies, we used a
concentration (30 nM) which is considered to be within the
physiological range [29]. Moreover, the length of exposure in our
experiments was limited to between two and four hours. We
observed no change in the normal membrane potential of
mitochondria, as evidenced by fluorescence of the vital dye, JC1
(Movies S3 and S4); hence, the inhibitory effect of dopamine on
mitochondrial movement that we observed is unlikely to be
attributable to an obvious impairment of mitochondria per se.
Moreover, administration of 5-HT, SCH23390, or SKF38393 (as
well as the other drugs used in the present study) did not induce
changes in mitochondrial membrane potential in hippocampal
neurons (unpublished data). This finding is consistent with a
published study that employed SH-SY5Y cells [28].
We found that dopamine has a net inhibitory effect on
mitochondrial movement in hippocampal neurons (Fig. 3A–C).
Subsequent experiments with different receptor-specific agonists
and antagonists revealed that this observed inhibition likely reflects
the net outcome of the opposing effects of different dopamine
receptor subtypes within the same cells. Specifically, a D2R
agonist inhibited mitochondrial movement (Fig. 4A–C), whereas a
D1R agonist promoted mitochondrial movement (Fig. 5A–C). The
extent of overlap between D1 and D2 receptors in another brain
region, the striatum, is still not completely resolved [30], although
recent work has shown that there is a substantial overlap of
expression in medium spiny neurons [31]. The results of our
immunocytochemistry experiments, in which we used receptor-
specific antibodies that had been previously employed by others
[19], indicate that, like neostriatal neurons, hippocampal neurons
in vitro express both subtypes of dopamine receptor (Figs. 1, 2).
However, it bears mentioning that cultured embryonic neurons (as
used in our studies) and neostriatal cultures [19] may exhibit
different patterns of dopamine receptor expression than that found
in the adult nervous system [19,32]. By employing selective D2R
and D1R agonists, we showed that the inhibition of mitochondrial
movement by D2R activation could be reversed by specifically
activating D1 receptors, provided that the D2R agonist was
washed out of the culture system. We can therefore conclude that,
in hippocampal neurons, D2R activation predominates, although
D1 receptors are also active.
Akt-GSK3b is a signaling cascade downstream of
dopamine in hippocampal neurons
From studies of the striatum, it is known that D1 and D2
receptors have opposing effects on adenylyl cyclase activity via
coupling to the different heterotrimeric G protein subunits [24,25].
This may explain some of the opposing effects of these two
dopamine receptor subtypes that we have observed. However, it
has also been recognized that the two types of dopamine receptor
may have different functions due to interactions with other
regulatory partners, as well as other kinds of receptors [33–35]. In
some cases, these interactions may be independent of the cAMP
pathway [11,36].
In our studies, stimulation of each of the two receptors subtypes
appeared to have opposite effects on the Akt-GSK3b signaling
pathway (Fig. 7B, lanes 2 and 4), indicating that the two receptors
converge on this pathway in hippocampal neurons. Given that we
observed a stimulatory effect on mitochondrial movement in
response to a D1R agonist, the results of our IBMX treatment
experiments appear to run counter to the predicted correlation
between elevated cAMP and DR1-coupled signaling, and
therefore will require more thorough characterization. Neverthe-
less, our results suggest, first, that cAMP is probably involved in
the regulation of Akt in hippocampal neurons in a manner that is
different from that observed in striatal neurons (Fig. 8C) and,
second, that cAMP likely plays a role in the regulation of
mitochondrial movement (Fig. 9A). Our finding, that treatment
with IBMX reduced levels of activated Akt in hippocampal
neurons after 15 minutes, fits within the proposed temporal
window of the actions of cAMP signals [11]. It is intriguing that
the onset of inhibition by D2R activation occurs within the same
time frame. Apropos of this fact, a plausible link between cAMP
and Akt might be PP2A, a phosphatase which can be activated by
PKA and is responsible for the dephosphorylation of Akt [10,37].
Although it has been suggested that D2 receptors, and not D1
Figure 5. SKF38393, a D1R agonist, promotes axonal transport of mitochondria in hippocampal neurons, whereas SCH23390, a
D1R antagonist inhibits mitochondrial transport (A–F). A–B and D–E. Mean speeds (mm/min) of individual mitochondria before and after
treatment with SKF38393 (33 mM; A,B) or SCH23390 (55 mM; D,E). Pie chart insets show the percentage of stationary (red), oscillatory (blue), and
directionally moving (green) mitochondria in all pooled experiments in the initial (a) and final (b) 15 minutes of imaging. C,F. Changes in mean
speeds of all directionally mitochondria over time following treatment with D1R agonists and antagonists. ‘‘(2)’’ indicates retrograde movement;
‘‘(+)’’ indicates anterograde movement. The red dotted lines projecting from the highlighted region of the schematic axon to the Y-axis of each graph
in A and B and E and F indicate the approximate location (,100–150 mm from the soma) and extent (,50–80 mm) of the axon segment that was
imaged.
doi:10.1371/journal.pone.0002804.g005
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in the striatum [12], other studies employing cultured striatal
neurons have shown that D1 receptors are also involved in the
regulation of cAMP-dependent Akt signaling [26].
Axonal movement of mitochondria and other cargoes requires
an association between the organelle and specific motor proteins,
which, in turn, mediate movement of cargoes on cytoskeletal
elements in an ATP-dependent manner [1]. Signals that alter the
interactions between mitochondria and motor proteins such as
KIF5, associated adapter proteins, such as miro, milton, and
syntabulin, or connections between motor proteins and the
cytoskeleton could have profound effects on mitochondrial
movement. It has been shown that Akt can induce actin
remodeling by direct phosphorylation of actin, and, notably,
many cytoskeletal components are GSK3b substrates [38]. It has
also been shown that Akt can be localized to mitochondria and
can phosphorylate the b-subunit of ATP synthase [39,40]. Thus,
Akt may directly affect the amount of ATP locally available to
drive molecular motors. Future work will be directed towards
identifying the downstream targets of the Akt-GSK3b signaling
cascade, which can account for the effect of dopamine on
mitochondrial movement.
The integrated effects of 5-HT and dopamine signals in
the regulation of mitochondrial movement
It has been noted that 5-HT and dopamine, as well as
noradrenaline, interact in a highly intricate manner [1,41–44].
However, the molecular bases of these interactions have not been
fully characterized. Our results reveal a novel interaction between
5-HT and dopamine that appears to involve the Akt-GSK3b
signaling pathway. Dopamine and 5-HT exert opposing effects on
mitochondrial trafficking in hippocampal neurons, and dopamine
appears to override the stimulatory effect of 5-HT on the speed of
mitochondrial movement. We hypothesize that the influence of
dopamine may be important for maintaining a homeostatic
distribution of mitochondria in hippocampal neurons. Consistent
with this hypothesis, it has been noted in earlier studies that a
homeostatic distribution of mitochondria in peripheral regions of
neurons—in particular, axons and dendrites—is critical for
maintaining proper function [1,45]. Striking a balance between
motile (that is, both directionally moving and oscillatory
populations) and stationary populations of mitochondria may
therefore be important for sustaining neuronal activity. Indeed, in
the axons of hippocampal neurons, large shifts in motile and non-
motile mitochondrial populations have been shown to cause
dramatic changes in levels of synaptic activity [46]. Previously, we
suggested that 5-HT promotes mitochondrial movement to meet
localized energy requirements in regions such as the axon
terminals [9]. The results of the present study suggest that
dopamine may serve to limit the redistribution of potential energy
sources.
A number of drugs designed to treat psychiatric disorders target
the serotonergic or dopamineric systems. For example, fluoxetine,
a selective serotonin reuptake inhibitor, is often prescribed for
depression, and haloperidol, a D2R antagonist, has been used
effectively in the treatment of schizophrenia. Together, the present
study and our previous report [9] show that such drugs can affect
mitochondrial movement directly via the Akt-GSK3 signaling
pathway, which itself can be a direct therapeutic target, as in the
administration of lithium to treat bipolar disorder. Our results
therefore suggest that the integrated influence of dopamine and 5-
HT signals on mitochondrial movement may be a critical factor in
the maintenance of normal brain function.
Figure 6. Modulation of mitochondrial movement by D2R and
D1R agonists is reversible. Kymographs of mitochondrial motility
shown in supplementary movies (Movies S13-S16); vertical scale
bar=10 minutes. In the experiment, a segment of axon was imaged
continuously for four hours (with short breaks to allow for exchange of
media and administration of drugs) at 10-second intervals. Hour 1:
before treatment, basal level of mitochondrial movement. Hour 2:
treatment with bromocriptine. Hour 3: washout of bromocriptine, and
addition of SKF38393. Hour 4: one hour incubation with SKF38393.
doi:10.1371/journal.pone.0002804.g006
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Primary cell culture
Primary cultures of rat hippocampal neurons were prepared
according to previously described methods with minor modifica-
tions [47]. Briefly, rat hippocampal cells were collected from E18
embryos and plated on poly-D-lysine (PDL)- and laminin-coated
35 mm glass-bottom dishes (MatTek, Ashland, MA) in DMEM
containing high glucose (25 mM) supplemented with B27, L-
asparagine, L-proline, and Vitamin B-12. This medium was used
after being conditioned on monolayers of cortical glia for
24 hours. Plating densities of hippocampal neurons were 2800
cells/cm
2 and 1200 cell/cm
2 in conventional 35-mm dishes for
protein assays and 35 mm glass-bottom dishes for imaging studies,
Figure 7. Dopamine signals are coupled to the activation of Akt and inactivation of GSK3b in hippocampal neurons (A–D). A. Western
blot analysis shows that treatment with dopamine (30 nM) for 60 minutes leads to the inactivation of Akt (i.e., decreased serine-473 phosphorylation)
and the activation of GSK3b (i.e., decreased serine-9 phosphorylation). B. Quantification of Western blots (n.3) showing the effect of dopamine alone
on the phosphorylation of Akt (top) and GSK3b (bottom). C. Treatment with a D2R agonist (Bromocriptine, 5 mM) or a D1R antagonist (SCH23390,
55 mM) for 60 minutes leads to the inactivation of Akt and the activation of GSK3b, whereas treatment with a D2R antagonist (Haloperidol, 10 mM) or
a D1R agonist (SKF23383, 33 mM) for 60 minutes leads to the activation of Akt and inactivation of GSK3b. D. Quantification of Western blots (n.3)
showing the effect of dopamine signals on the phosphorylation of Akt (top) and GSK3b (bottom). Whole cell extracts from hippocampal neuronal
cultures (DIV 17) were used in Western blots. In B and D, intensity values were normalized to total Akt or total GSK3b values.
doi:10.1371/journal.pone.0002804.g007
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used at 17–21 DIV in time-lapse imaging studies. On the fourth
day after initial plating and every four days thereafter, Ara-C was
added to control growth of glial populations. All chemical reagents
were purchased from Sigma-Aldrich (St. Louis, MO) unless
otherwise specified.
Infection of cell culture
To allow visualization of mitochondria during live-cell imaging
by fluorescence microscopy, cells were infected at 14 DIV with a
Feline Immunodeficiency Virus (FIV)-based vector lentivirus,
designated Flx1.8/CMVMitoEYFP, which encodes a MitoEYFP
transgene (Clontech, Mountain View, CA). A second lentivirus
was made, designated Flx1.8/CMVMitoTurboRFP, in order to
label mitochondria with a red fluorescent protein (Axxora, San
Diego, CA). Pseudotyped virus was generated by co-transfecting
293T cells with the transfer vector together with plasmids
encoding the vesicular stomatitis virus G-glycoprotein (VSVG)
and FIV gag-pol genes [48]. Viral titer was estimated by flow
cytometry of infected B104 cells, and a quantity of virus was used
that was sufficient to obtain an infection efficiency of 30–40%.
Following infection, cells were allowed three or more days to
accumulate a sufficiently strong EYFP signal before proceeding
with live imaging.
Life support for primary cultures during microscopy
To perform live-cell imaging experiments, we used a micro-
scope stage-top incubator that we had previously designed and
built to enclose a 35mm glass-bottom culture dish [9]. This
incubator both provides an atmosphere of 90% air/10% CO2
(Airgas, Inc., San Diego, CA) and maintains ambient air and stage
temperatures at 37uC. The incubator system enables us to
Figure 8. Treatment with IBMX has different effects on hippocampal neurons and striatal neurons (A–C). A. Inhibition of mitochondrial
movement by IBMX. Mean speed (mm/min) of all directionally moving mitochondria from pooled experiments before and after treatment with IBMX
(100 mM; n=5, paired t-test; p,0.02). B. Western blot analysis shows that administration of IBMX (100 mM) reduces Akt activity in hippocampal
neurons, which is represented by decreased levels of phosphorylated serine-473 of Akt, relative to total Akt, over time. C. Western blot analysis shows
that administration of IBMX (100 mM) increases Akt activity in striatal neurons, which is represented by decreased levels of phosphorylated serine-473
of Akt, relative to total Akt, over time.
doi:10.1371/journal.pone.0002804.g008
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on the microscope stage top over many hours, or even days.
Live cell imaging
Fluorescence microscopy was used to observe axonal transport
of EYFP-labeled mitochondria in live hippocampal neurons.
Time-lapse image series were acquired under high magnification
(636 PLAN APO oil immersion objective; numerical aper-
ture=1.32; Leica, GmbH, Germany) using a Leica DMI-6000B
inverted fluorescence microscope (Leica GmbH, Germany)
equipped with a Sutter Lamda 10-2 emission filter wheel, Sutter
DG-4 xenon light source (Sutter Instruments, Novato, CA), and a
Cooke Sensiscam qe
TM cooled CCD camera (Cooke Corporation,
Romulus, MI). Microscope control, image capture, post-process-
Figure 9. Dopamine and 5-HT exert opposing effects on mitochondrial movement and Akt activity (A–D). Mean speeds of directionally
moving mitochondrial populations are shown at two hour intervals in A and C. Akt activity levels in cultures after treatment with DA and 5-HT are
shown in B and D. Mitochondrial movement was measured following serial administration of dopamine or its receptor agonists, antagonists, and 5-
HT. In these experiments, a 6 hour period of observation was divided into three two-hour intervals, each allocated for a different treatment, i.e.,
control (CTL), dopamine (DA), or 5-HT. A. Prior to treatment with 5-HT, hippocampal neurons were pretreated with dopamine receptor-specific
agonists or antagonists, including DA, SKF38393, SCH2390, haloperidol, and bromocriptine. B. Western blot analysis shows that dopamine
counteracts the effect of 5-HT on Akt activity in the presence of 5-HT. C. Prior to treatment with dopamine signals, hippocampal neurons were
pretreated with 5-HT. Each mean speed value in the graph represents three repeat experiments, i.e., separately prepared cultures (n=3, paired t-test;
p,0.02; 103–130 mitochondria were tracked in calculating the average speeds of each set of mitochondria in a given treatment interval). D. Western
blot analysis shows that 5-HT failed to counteract the effect of dopamine on Akt activity in the presence of dopamine. All other conditions are the
same as previously described in Figs. 3–5.
doi:10.1371/journal.pone.0002804.g009
Dopamine and Mitochondria
PLoS ONE | www.plosone.org 12 July 2008 | Volume 3 | Issue 7 | e2804ing, and particle tracking of mitochondria were all accomplished
using the Slidebook
TM image acquisition and analysis software
package (Intelligent Imaging Innovations, Inc., Denver, CO). In
each imaging session, individual frames of mitochondria within an
axon segment were acquired every 30 seconds (except where
noted) for a total recording time of two hours. Cells were imaged
for two hours before and two hours after administration of drugs.
For masking purposes, each individual mitochondrion within a
given axon segment of interest was distinguishable by its
morphology (e.g., size, shape, position, and signal intensity) and
behavior (e.g., pattern of movement), due in large measure to the
intensity and stability of the EYFP signal.
Image analysis
Using Slidebook
TM, masks of individual mitochondria were
generated, and the center of area (centroid) of each mask was
determined. Masks for stationary and oscillatory mitochondria
were generated by Slidebook
TM; masks of directionally moving
mitochondria were generated manually. The ID tag of each
individual mitochondrion was verified by carefully reviewing
movie files frame-by-frame to ensure continuity over the course of
the image series, and ambiguous labels were discarded. Manual
masking was performed in a double-blind procedure. The
individual executing this procedure did not know whether a given
time-lapse image series was acquired before treatment or after
treatment. Coordinates of the centroids of masked mitochondria
were then obtained using the particle tracking module within
Slidebook
TM. The parameters used for characterizing the
movement of each mitochondrion (e.g., individual label assign-
ment, displacement, speed) were calculated from recorded changes
in their X-Y coordinates. The displacement plots shown in Figs. 3–
5 therefore represent the mean speeds (mm/min) of each individual
mitochondrion over the full duration of each imaging session.
Mean speeds are shown on the abscissa and the relative positions
of individual mitochondrion along the axon segments are shown
on the ordinate. Pie charts represent the initial and final
proportions of each population category represented in the total
pool of experiments. Speed plots represent the mean speeds of
pooled directionally moving populations from all experiments,
calculated at 15 minute intervals. Standard error bars represent
standard errors of the mean (6SEM) calculated from the total pool
of experiments; in all cases, paired Student’s t-tests were applied to
determine significance. Kymographs shown in Figure 6 were
generated by the ‘smooth curve analysis’ module in Slidebook
TM.
Immunohistochemical staining
EYFP-labeled hippocampal neurons cultured on glass-bottom
culture dishes were fixed in 4% paraformaldehyde (pH 7.4) for
20 minutes. The cells were then permeabilized in PBT buffer
(0.01% Tween-20, 0.02% BSA in PBS) for 40 minutes at room
temperature. Following this, the cells were first incubated with
mouse monoclonal antibody (primary antibody) for 1 hour. The
cells were then incubated with a secondary fluorescein-labeled
antibody for 1 hour. Finally, cells were covered in ProLong GoldH
antifade reagent (Invitrogen, Carlsbad, CA) before a coverslip was
applied and images were aquired. Primary antibodies used for
staining were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA) and Chemicon (Temecula, CA). Secondary antibodies
were purchased from Invitrogen (Carlsbad, CA).
Western blotting
Western blotting was performed to determine levels of kinase
activation. Cells were harvested in RIPA buffer (Tris-HCl:
50 mM, pH7.4, NP-40: 1%, Na-deoxycholate: 0.25%, NaCl:
150 mM, EDTA: 1 mM, PMSF: 1 mM, Aprotinin, leupeptin,
pepstatin: 1 ug/ml each, Na3VO4: 1 mM, NaF: 1 mM). Samples
were run on 10% SDS-polyacrylamide gels (Invitrogen, Carlsbad,
CA). Western blotting was performed using primary antibodies to
phospho-ser9-GSK3b, total GSK3b, phospho-ser473-Akt, and
total Akt (Cell Signaling Technology, Danvers, MA). The
secondary antibodies used for Western blotting were horseradish
peroxidase (HRP)-conjugated (Jackson ImmunoResearch Labora-
tories, Inc., West Grove, PA), and blots were developed using ECL
(GE Healthcare,Piscataway, NJ). For quantification, Western blots
were scanned and intensity values were determined using Scion
Image (Scion Corporation, Frederick, MD).
Supporting Information
Figure S1 Dopamine has a sustained inhibitory effect on the
activity of Akt. Western blot analysis shows that administration of
dopamine (30 nM) reduced Akt activity in hippocampal neurons
(as represented by the phosphorylation of serine-473 of Akt) over
time.
Found at: doi:10.1371/journal.pone.0002804.s001 (10.14 MB
TIF)
Figure S2 D1 and D2 receptors exert opposing effects on each
other. Western blot analysis shows that D1 and D2 receptor
activation has opposing effects on Akt activity (as represented by
the phosphorylation of serine-473) in hippocampal neurons. In
these experiments, hippocampal neurons were treated with the
first drug for one hour. Following washout of the first drug
(receptor-specific agonist or antagonist), the second drug was
applied, and after one hour, total cell lysates were collected.
Found at: doi:10.1371/journal.pone.0002804.s002 (8.50 MB TIF)
Movie S1 Mitochondrial motility before treatment with Dopa-
mine. Time-lapse series showing motility of EYFP-labeled
mitochondria in cultured hippocampal neurons for two hours
before administration of dopamine.
Found at: doi:10.1371/journal.pone.0002804.s003 (0.77 MB
MOV)
Movie S2 Mitochondrial motility after treatment with Dopa-
mine. Time-lapse series showing motility of EYFP-labeled
mitochondria in cultured hippocampal neurons for two hours
after administration of dopamine.
Found at: doi:10.1371/journal.pone.0002804.s004 (1.17 MB
MOV)
Movie S3 Mitochondrial membrane potential after treatment
with Dopamine. Time-lapse series showing stability of mitochon-
drial membrane potential in mitochondria labeled with the vital
dye JC-1 after administration of dopamine.
Found at: doi:10.1371/journal.pone.0002804.s005 (0.43 MB
MOV)
Movie S4 Mitochondrial membrane potential after treatment
with FCCP. Time-lapse series showing changes in mitochondrial
membrane potential in mitochondria labeled with the vital dye JC-
1 after administration of FCCP.
Found at: doi:10.1371/journal.pone.0002804.s006 (0.29 MB
MOV)
Movie S5 Mitochondrial motility before treatment with Bromo-
criptine, a D2R agonist. Time-lapse series showing motility of
EYFP-labeled mitochondria in cultured hippocampal neurons for
two hours before administration of Bromocriptine, a D2R agonist.
Found at: doi:10.1371/journal.pone.0002804.s007 (1.61 MB
MOV)
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criptine, a D2R agonist. Time-lapse series showing motility of
EYFP-labeled mitochondria in cultured hippocampal neurons for
two hours after administration of Bromocriptine, a D2R agonist.
Found at: doi:10.1371/journal.pone.0002804.s008 (1.01 MB
MOV)
Movie S7 Mitochondrial motility before treatment with Halo-
peridol, a D2R antagonist. Time-lapse series showing motility of
EYFP-labeled mitochondria in cultured hippocampal neurons for
two hours before administration of Haloperidol, a D2R antago-
nist.
Found at: doi:10.1371/journal.pone.0002804.s009 (5.45 MB
MOV)
Movie S8 Mitochondrial motility after treatment with Haloper-
idol, a D2R antagonist. Time-lapse series showing motility of
EYFP-labeled mitochondria in cultured hippocampal neurons for
two hours after administration of Haloperidol, a D2R antagonist.
Found at: doi:10.1371/journal.pone.0002804.s010 (9.48 MB
MOV)
Movie S9 Mitochondrial motility before treatment with
SKF38393, a D1R agonist. Time-lapse series showing motility of
EYFP-labeled mitochondria in cultured hippocampal neurons for
two hours before administration of SKF38393, a D1R agonist.
Found at: doi:10.1371/journal.pone.0002804.s011 (3.58 MB
MOV)
Movie S10 Mitochondrial motility after treatment with
SKF38393, a D1R agonist. Time-lapse series showing motility of
EYFP-labeled mitochondria in cultured hippocampal neurons for
two hours after administration of SKF38393, a D1R agonist.
Found at: doi:10.1371/journal.pone.0002804.s012 (3.73 MB
MOV)
Movie S11 Mitochondrial motility before treatment with
SCH23390, a D1R antagonist. Time-lapse series showing motility
of EYFP-labeled mitochondria in cultured hippocampal neurons
for two hours before administration of SCH23390, a D1R
antagonist.
Found at: doi:10.1371/journal.pone.0002804.s013 (6.55 MB
MOV)
Movie S12 Mitochondrial motility after treatment with
SCH23390, a D1R antagonist. Time-lapse series showing motility
of EYFP-labeled mitochondria in cultured hippocampal neurons
for two hours after administration of SCH23390, a D1R
antagonist.
Found at: doi:10.1371/journal.pone.0002804.s014 (1.22 MB
MOV)
Movie S13 Mitochondrial motility before treatment with
Bromocriptine. Time-lapse series showing basal motility of
EYFP-labeled mitochondria in cultured hippocampal neurons
for two hours before administration of Bromocriptine.
Found at: doi:10.1371/journal.pone.0002804.s015 (3.15 MB
MOV)
Movie S15 Mitochondrial motility following washout - first
hour. Time-lapse series showing mitochondrial motility in the first
hour following the washout of bromocriptine and subsequent
treatment with SKF38393, a D1 agonist.
Found at: doi:10.1371/journal.pone.0002804.s016 (0.24 MB
MOV)
Movie S14 Mitochondrial motility after treatment with Bromo-
criptine. Time-lapse series showing mitochondrial motility follow-
ing treatment with bromocriptine.
Found at: doi:10.1371/journal.pone.0002804.s017 (0.86 MB
MOV)
Movie S16 Mitochondrial motility following washout - second
hour. Time-lapse series showing mitochondrial motility in the
second hour following washout of Bromocriptine and treatment
with SKF38393.
Found at: doi:10.1371/journal.pone.0002804.s018 (0.52 MB
MOV)
Movie S17 Mitochondrial motility before treatment with IBMX.
Time-lapse series showing mitochondrial motility before treatment
with IBMX.
Found at: doi:10.1371/journal.pone.0002804.s019 (3.71 MB
MOV)
Movie S18 Mitochondrial motility after treatment with IBMX.
Time-lapse series showing mitochondrial motility following
treatment with IBMX.
Found at: doi:10.1371/journal.pone.0002804.s020 (0.71 MB
MOV)
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